Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Clene Inc.NASDAQ: CLNN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$6.94M, compared with $261K a year earlier. Trailing-twelve-month EBITDA was -$29.2M.
Context
- EBITDA amounted to 10998.0% of revenue in FY2025, up 1146.8 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$16.37M (+25.6%) for the fiscal year ending Dec 2026, a slowdown from the +34.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.94M+14.5% QoQ
- Last fiscal yearDec 2025
- -$22M+34.7% YoY
- LTMMar 2026
- -$29.2M-21.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2760.9% | +31.8% | +2792.7 pp |
| 1 year | +34.7% | +25.6% | -9.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (22M) USD
- Year-over-year change
- +34.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22M) | +34.7% |
| FY2024 | 2024-12-31 | (33.69M) | +22.1% |
| FY2023 | 2023-12-31 | (43.24M) | -68.9% |
| FY2022 | 2022-12-31 | (25.6M) | -206.9% |
| FY2021 | 2021-12-31 | (8.34M) | — |
EBITDA vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 EBITDA of -$29.2M is the 4th highest of the 11 companies compared; the peer median is -$48.43M.
- Its year-over-year change of -21.6% is the 8th highest of 11, against a peer median of +0.4%.
- EBITDA amounts to 21792.5% of revenue for CLNN, versus a peer median of 337.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M | +1391.3% | — | — | |
| LTM Mar 2026 | -$21.1M | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$29.2M | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$40.18M | -45.5% | — | — | |
| LTM Mar 2026 | -$46.23M | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| FY2025 | -$54.58M | -270.2% | — | 85279.7% | |
| LTM Mar 2026 | -$107.98M | +49.6% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M | +37.9% | — | — | |
| Peer median (excluding CLNN) | -$48.43M | +0.4% | — | 337.0% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 723K | 473K | 654K | 342K | 200K |
| Cost of Revenue | 289K | 26K | 121K | 70K | 43K |
| Gross Profit | 434K | 447K | 533K | 272K | 157K |
| Gross Margin | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Research & Development | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
| Selling, General & Admin | 18.81M | 16.16M | 14.42M | 13.31M | 9.23M |
| Operating Expenses | 50.41M | 48.86M | 41.07M | 33.37M | 23.24M |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| EBITDA | (8.34M) | (25.6M) | (43.24M) | (33.69M) | (22M) |
| EBITDA Margin | -1153.9% | -5412.9% | -6611.8% | -9851.2% | -10998.0% |
| Operating Income | (49.98M) | (48.41M) | (40.54M) | (33.09M) | (23.08M) |
| Operating Margin | -6912.6% | -10234.5% | -6198.8% | -9676.3% | -11541.5% |
| Interest Income | 0 | 0 | 1.39M | 865K | 223K |
| Interest Expense | 870K | 3.3M | 4.56M | 4.06M | 2.68M |
| Other Income / Expenses | 39.81M | 18.49M | (8.96M) | (6.31M) | (3.09M) |
| Income Before Tax | (10.17M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Pre-Tax Margin | -1406.4% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| Income Tax Expense | (428K) | 0 | 0 | 0 | 0 |
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Net Margin | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| EPS (Basic) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| EPS (Diluted) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| Weighted Avg Shares | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Weighted Avg Shares (Diluted) | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.